Dr. Reddy's Scores Global Cancer Drug Coup with Immutep's Eftilagimod Alfa Licensing Deal

Immutep SAS and Dr. Reddy's Laboratories SA announced a strategic collaboration on December 8, 2025, for eftilagimod alfa, a first-in-class immunotherapy activating antigen-presenting cells to fight cancer via LAG-3 and MHC Class II mechanisms. Efti targets solid tumors, headlining a Phase III trial (TACTI-004/KEYNOTE-F91) for first-line non-small cell lung cancer (NSCLC) with pembrolizumab and chemotherapy, plus studies in head & neck cancer, breast cancer, and sarcoma. Immutep retains rights in premium markets and global manufacturing, supplying Dr. Reddy's for emerging regions.​

Key Highlights

Financials: $20M upfront (~AUD 30.2M) to Immutep; up to $349.5M (~AUD 528.4M) in milestones; double-digit royalties on sales.​

Territory: Exclusive to Dr. Reddy's in all countries excluding North America, Europe, Japan, Greater China.​

Exec Quotes: "Ideal partner to maximize impact," says Immutep CEO Marc Voigt; "New standard of care potential," notes Dr. Reddy's M.V. Ramana.​

Pipeline Momentum: FDA Fast Track for NSCLC/HNSCC; favorable safety for combos with PD-1 therapy, chemo, radiation.​

Sources: GlobeNewswire (Immutep Release), Express Pharma, Economic Times.​